Cordis releases stent study data

Interventional technology developer Cordis Endovascular has released data from four international clinical studies for its Cypher sirolimus-eluting coronary stent at the 2004 Paris Course on Revascularization (PCR) this week in Paris.

The stent is designed to treat higher-risk and challenging blockages in coronary arteries, including small-vessel blockages, chronic total occlusions, in-stent restenosis, and multivessel disease, according to the Warren, NJ-based firm.

The studies -- Svelte, for small coronary arteries; Tropical for in-stent restenosis; Sicto, for chronic total occlusions; and Arts II, for sirolimus-eluting stents versus coronary artery bypass graft (CABG) in the treatment of multivessel disease -- showed that the Cypher stent significantly reduced recurrent blockage of arteries from compared with results seen with conventional bare-metal stents, Cordis said.

By staff writers
May 26, 2004

Related Reading

Cordis recalls instructions for biliary stent, May 10, 2004

Cordis stent gets FDA panel recommendation, April 22, 2004

Cordis stent gets CE OK, April 8, 2004

Guidant, Johnson & Johnson ink stent deal, February 27, 2004

Cordis stent gets FDA OK, September 5, 2003

Copyright © 2004

Page 1 of 374
Next Page